Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
satb1 siRNA is a small interfering RNA designed to silence the expression of Special AT-rich sequence-binding protein 1 (SATB1). SATB1 is a global chromatin organizer and transcription factor that tethers genomic DNA to the nuclear matrix, facilitating the three-dimensional organization of chromatin. In the context of esophageal squamous cell carcinoma (ESCC), SATB1 has been identified as a prognostic factor that promotes tumor cell migration and invasion, potentially through the regulation of matrix metalloproteinase 3 (MMP3). By knocking down SATB1 expression, this siRNA inhibits the aggressive phenotype of cancer cells, suggesting its potential as a therapeutic strategy for SATB1-overexpressing malignancies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on satb1 siRNA.